HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories
DIVI.NS reported a better-than-expected quarterly profit on
Monday, aided by strong performance of its business that focuses
on customised production of chemical compounds used in drugs,
sending its shares higher.
The company's consolidated net profit jumped 64.5% to 5.89
billion rupees ($67.6 million) in the third quarter, slightly
above analysts' estimates of 5.13 billion rupees, as per LSEG
data.
The Hyderabad-based drugmaker's shares reversed course from
a 0.2% dip to trade 3.3% higher after the results.
Divi's is one of India's largest manufacturers of active
pharmaceutical ingredients (API), key components of a drug that
produce the intended therapeutic effects. Its client list spans
more than 100 countries and includes major drugmakers such as
Novartis NOVN.S .
Its revenue from operations climbed 25% to 23.19 billion
rupees during the quarter, roughly in line with analysts'
estimate of 23.43 billion rupees.
The company also provides contract development and
manufacturing (CDMO) services. Divi's and its local peers stand
to gain as major drugmakers are diversifying their supply chain
to limit their reliance on China.
Divi's, in particular, has said it is also banking on demand
from obesity drug manufacturers as they scramble to meet
skyrocketing customer demand.
However, its generics business, much like those of its
peers, is facing pricing pressure, a situation it hopes will
stabilise this year.
($1 = 87.1190 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon; Editing by
Rashmi Aich and Savio D'Souza)
((Rishika.Sadam@thomsonreuters.com;))